In this work a novel capillary electrophoresis-mass spectrometry (CE-MS) based method was developed and validated for the assay of β-secretase (BACE1) activity as a potential target for Alzheimer's disease (AD) treatment. In contrast with the typically used Förster resonance energy transfer (FRET) assays, an unlabelled decapeptide derived from the amyloid precursor protein BACE1 site with the "Swedish mutation" was used as the substrate. The CE usage enabled the enzymatic reaction to be carried out in as small a volume as 100μL in 60min with sufficient yields of proteolytic product, which was subsequently separated in a bare fused silica capillary using 12.5% acetic acid as a background electrolyte and detected by MS. The limits of detection and quantitation were estimated using the signal to noise ratio to be 5nM (S/N=3) and 15nM (S/N=10), respectively, both being well below the working range for kinetic and inhibition studies. Its applicability for the kinetic study of BACE1 was demonstrated using optimized enzyme assay conditions and the estimated kinetic parameter values were confirmed by classic CE-UV analyses. The method was finally used for the main purpose for which it was developed - to screen BACE1 inhibitors as potential AD therapeutics. The resulting kinetic and inhibition parameters values were compared to those published in the literature, which were almost exclusively obtained by FRET based assays. These comparisons brought up several issues that are further discussed below and favour the application of an unlabelled substrate. The proposed CE-MS based method offers a high-throughput capability for new drug development.

Department of Biochemistry Faculty of Science Masaryk University Kamenice 5 625 00 Brno Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc17013273

003      

CZ-PrNML

005      

20170502094604.0

007      

ta

008      

170413s2017 ne f 000 0|eng||

009      

AR

024    7_

$a 10.1016/j.chroma.2017.01.057 $2 doi

035    __

$a (PubMed)28153449

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a ne

100    1_

$a Schejbal, Jan $u Department of Biochemistry, Faculty of Science, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.

245    12

$a A capillary electrophoresis-mass spectrometry based method for the screening of β-secretase inhibitors as potential Alzheimer's disease therapeutics / $c J. Schejbal, L. Slezáčková, R. Řemínek, Z. Glatz,

520    9_

$a In this work a novel capillary electrophoresis-mass spectrometry (CE-MS) based method was developed and validated for the assay of β-secretase (BACE1) activity as a potential target for Alzheimer's disease (AD) treatment. In contrast with the typically used Förster resonance energy transfer (FRET) assays, an unlabelled decapeptide derived from the amyloid precursor protein BACE1 site with the "Swedish mutation" was used as the substrate. The CE usage enabled the enzymatic reaction to be carried out in as small a volume as 100μL in 60min with sufficient yields of proteolytic product, which was subsequently separated in a bare fused silica capillary using 12.5% acetic acid as a background electrolyte and detected by MS. The limits of detection and quantitation were estimated using the signal to noise ratio to be 5nM (S/N=3) and 15nM (S/N=10), respectively, both being well below the working range for kinetic and inhibition studies. Its applicability for the kinetic study of BACE1 was demonstrated using optimized enzyme assay conditions and the estimated kinetic parameter values were confirmed by classic CE-UV analyses. The method was finally used for the main purpose for which it was developed - to screen BACE1 inhibitors as potential AD therapeutics. The resulting kinetic and inhibition parameters values were compared to those published in the literature, which were almost exclusively obtained by FRET based assays. These comparisons brought up several issues that are further discussed below and favour the application of an unlabelled substrate. The proposed CE-MS based method offers a high-throughput capability for new drug development.

650    _2

$a Alzheimerova nemoc $x farmakoterapie $7 D000544

650    _2

$a sekretasy $x antagonisté a inhibitory $7 D053829

650    _2

$a aspartátové endopeptidasy $x antagonisté a inhibitory $7 D016282

650    _2

$a preklinické hodnocení léčiv $x metody $7 D004353

650    _2

$a elektroforéza kapilární $x metody $7 D019075

650    _2

$a HEK293 buňky $7 D057809

650    _2

$a lidé $7 D006801

650    _2

$a kinetika $7 D007700

650    _2

$a hmotnostní spektrometrie $x metody $7 D013058

650    _2

$a inhibitory proteas $x analýza $x terapeutické užití $7 D011480

655    _2

$a časopisecké články $7 D016428

655    _2

$a validační studie $7 D023361

700    1_

$a Slezáčková, Lucie $u Department of Biochemistry, Faculty of Science, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.

700    1_

$a Řemínek, Roman $u Department of Biochemistry, Faculty of Science, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.

700    1_

$a Glatz, Zdeněk $u Department of Biochemistry, Faculty of Science, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic. Electronic address: glatz@chemi.muni.cz.

773    0_

$w MED00004962 $t Journal of chromatography. A $x 1873-3778 $g Roč. 1487, č. - (2017), s. 235-241

856    41

$u https://pubmed.ncbi.nlm.nih.gov/28153449 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20170413 $b ABA008

991    __

$a 20170502094930 $b ABA008

999    __

$a ok $b bmc $g 1199738 $s 974051

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2017 $b 1487 $c - $d 235-241 $e 20170123 $i 1873-3778 $m Journal of chromatography. A, Including electrophoresis and other separation methods $n J Chromatogr A $x MED00004962

LZP    __

$a Pubmed-20170413